Analyst Reco. Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2026-04-15 pm EDT			5-day change	1st Jan Change
753.93 ^USD	-0.21%		-0.83%	-2.32%

Apr. 13	Regeneron Pharmaceuticals, Inc. and Telix Pharmaceuticals Limited Announce Strategic Radiopharma Collaboration	CI
Apr. 13	Regeneron, Telix Enter Radiopharma Collaboration; Telix Shares Up Pre-Bell	MT

Analyst Reco.

Apr. 08	Bernstein Adjusts Regeneron Pharmaceuticals Price Target to $921 From $925, Maintains Outperform Rating	MT
Apr. 07	RBC Adjusts Price Target on Regeneron Pharmaceuticals to $779 From $765, Maintains Sector Perform Rating	MT
Apr. 06	Raymond James Adjusts Price Target on Regeneron Pharmaceuticals to $910 From $870, Maintains Outperform Rating	MT
Mar. 19	Wells Fargo Adjusts Price Target on Regeneron Pharmaceuticals to $825 From $800, Maintains Equalweight Rating	MT
Mar. 11	Jefferies Adjusts Price Target on Regeneron Pharmaceuticals to $890 From $885, Maintains Buy Rating	MT
Mar. 02	RBC Raises Price Target on Regeneron Pharmaceuticals to $765 From $745, Keeps Sector Perform Rating	MT
Feb. 20	BMO Capital Adjusts Price Target on Regeneron Pharmaceuticals to $900 From $850, Maintains Outperform Rating	MT
Feb. 13	HSBC Adjusts Price Target on Regeneron Pharmaceuticals to $990 From $985, Maintains Buy Rating	MT
Feb. 10	Regeneron Pipeline Progress Continues but Near-Term Visibility Remains Limited, RBC Says	MT
Feb. 09	Rothschild & Co Redburn Adjusts Price Target on Regeneron Pharmaceuticals to $950 From $940, Maintains Buy Rating	MT
Feb. 09	Guggenheim Adjusts Price Target on Regeneron Pharmaceuticals to $975 From $865, Maintains Buy Rating	MT
Feb. 02	Cantor Fitzgerald Adjusts Price Target on Regeneron Pharmaceuticals to $800 From $740, Maintains Overweight Rating	MT
Feb. 02	JPMorgan Adjusts Price Target on Regeneron Pharmaceuticals to $950 From $850, Maintains Overweight Rating	MT
Feb. 02	Bernstein Adjusts Price Target on Regeneron Pharmaceuticals to $925 From $916, Maintains Outperform Rating	MT
Feb. 02	Oppenheimer Raises Price Target on Regeneron Pharmaceuticals to $865 From $750, Keeps Outperform Rating	MT
Jan. 29	TD Cowen Adjusts Regeneron Pharmaceuticals PT to $820 From $800, Maintains Buy Rating	MT
Jan. 28	Wolfe Adjusts Price Target on Regeneron Pharmaceuticals to $900 From $800, Maintains Outperform Rating	MT
Jan. 27	Regeneron's Eylea, Dupixent Should Support $625 Valuation Despite Competition, RBC Says	MT
Jan. 27	Bernstein Adjusts PT on Regeneron Pharmaceuticals to $916 From $911, Maintains Outperform Rating	MT
Jan. 26	Rothschild & Co. Redburn Adjusts PT on Regeneron Pharmaceuticals to $940 From $910, Maintains Buy Rating	MT
Jan. 23	Analyst recommendations: Amgen, P&G, Spotify, Duolingo, Moderna…
Jan. 22	Evercore ISI Adjusts Price Target on Regeneron Pharmaceuticals to $875 From $750, Maintains Outperform Rating	MT
Jan. 20	RBC Cuts Price Target on Regeneron Pharmaceuticals to $745 From $766, Keeps Sector Perform Rating	MT
Jan. 13	Jefferies Adjusts Price Target on Regeneron Pharmaceuticals to $885 From $870, Maintains Buy Rating	MT
Jan. 13	Raymond James Adjusts PT on Regeneron Pharmaceuticals to $820 From $800, Keeps Outperform Rating	MT